Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iEuroEwing trial for treatment optimisation in Ewing sarcoma
2022-501180-40-00Phase 3Authorised
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Jun 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of vinorelbine, cyclophosphamide, doxorubicin, ifosfamide, vincristine and 3 more in Ewing sarcoma and Ewing-like sarcoma (6 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoints: Event-free survival in standard-risk disease, Acute skin toxicity during radiotherapy and 1 more. Planned start Jun 2022; status: authorised.
02
Drugs
vinorelbinecyclophosphamidedoxorubicinifosfamidevincristine
03
Conditions
Ewing sarcomaEwing-like sarcoma
Beyond the preview
Go deeper on 2022-501180-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501180-40-00.